Innate Pharma (IPHA) Cash from Discontinued Operations (2020 - 2025)
Innate Pharma (IPHA) posted quarterly Cash from Discontinued Operations of 60032777.58 for Q4 2025, down 665.01% year-on-year from 10625106.75 in Q4 2024, and down 665.01% on a QoQ basis from 7847332.65 in Q4 2024.
Innate Pharma (IPHA) Cash from Discontinued Operations (2020 - 2025) Analysis & Trends
Innate Pharma (IPHA) has reported Cash from Discontinued Operations for 6 consecutive years, with 60032777.58 the latest figure, recorded in Q4 2025.
- Quarterly Cash from Discontinued Operations fell 665.01% year-over-year to 60032777.58 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 117977409.07 (down 47.95% YoY) and the FY2025 annual result came in at 60032777.58, down 665.01% from the prior year.
- Cash from Discontinued Operations declined to 60032777.58 in Q4 2025 per IPHA's latest filing, from 7847332.65 in the prior quarter.
- Over the last five years, Cash from Discontinued Operations for IPHA reached as high as 7847332.65 in Q4 2024 and fell as low as 66521392.83 in Q4 2021.
- A 5-year average of 34536749.57 and a median of 35460931.0 in 2021 frame the typical range for Cash from Discontinued Operations.
- Annual changes were most pronounced in 2024 — Cash from Discontinued Operations surged 78.82% — and 2025, when it plunged 665.01%.
- Year by year, Cash from Discontinued Operations stood at 66521392.83 in 2021, then jumped by 67.23% to 21797514.06 in 2022, then sank by 69.98% to 37050653.12 in 2023, then jumped by 78.82% to 7847332.65 in 2024, then tumbled by 665.01% to 60032777.58 in 2025.
- According to Business Quant data, Cash from Discontinued Operations over the past three periods registered 60032777.58, 7847332.65, and 37050653.12 for Q4 2025, Q4 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Innate Pharma | 157.68 Mn | 157.68 Mn | - | -60.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -60.03 Mn |
| Dec 31, 2025 | -60.03 Mn |
| Dec 31, 2024 | -7.85 Mn |
| Dec 31, 2024 | -7.85 Mn |
| Dec 31, 2023 | -37.05 Mn |
| Dec 31, 2023 | -37.05 Mn |
| Jun 30, 2023 | -13.05 Mn |
| Jun 30, 2023 | -13.05 Mn |
| Dec 31, 2022 | -21.80 Mn |
| Dec 31, 2022 | -21.80 Mn |
| Dec 31, 2021 | -66.52 Mn |
| Dec 31, 2021 | -66.52 Mn |
| Jun 30, 2021 | -35.46 Mn |
| Jun 30, 2021 | -35.46 Mn |
| Dec 31, 2020 | -58.91 Mn |
| Dec 31, 2020 | -58.91 Mn |
| Jun 30, 2020 | -66.03 Mn |
| Jun 30, 2020 | -66.03 Mn |